ATYR1923

Status
Phase 1
Condition
Sarcoidosis ILD
Intervention Type
Intravenous (IV) Injection
Funder Type
Industry

Drug Details

ATYR1923 is a selective modulator of NRP-2 that downregulates the innate and adaptive immune response in inflammatory disease states. 

Study Purpose

This randomized, double-blind, placebo-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK), and preliminary efficacy of multiple ascending doses of IV ATYR1923 in patients with pulmonary sarcoidosis undergoing a protocol-guided oral corticosteroid (OCS) tapering regimen.This study will consist of 3 staggered multiple dose cohorts. Each eligible participant will participate in only one cohort during the study. Within each cohort, 12 participants will be randomized 2:1 to ATYR1923 (N=8) or placebo (N=4).

Find a Clinical Trial

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >